Lung Cancer

Avastin (bevacizumab)
was approved today in Europe for the first-line treatment

Avastin is the first and only anti-angiogenic agent which has been shown to consistently deliver improved overall and/or progression-free survival for patients with colorectal, lung, breast and kidney cancer.